In Vivo Model Development for Obesity

Protheragen offers a comprehensive in vivo obesity model development service, supporting pharmaceutical, biotechnology, and academic partners in the discovery and evaluation of anti-obesity therapeutics. Leveraging a diverse repertoire of validated animal models, our team provides tailored solutions to address the complex etiology of obesity, ensuring translational relevance and robust preclinical data for your research and development programs.

Obesity is a multifactorial disease with significant global health implications, necessitating advanced preclinical models to unravel its pathophysiology and evaluate novel interventions. At Protheragen, we utilize a broad spectrum of animal species—including mice (Mus musculus), rats (Rattus norvegicus), hamsters, dogs, monkeys, pigs, rabbits, zebrafish, fruit flies, and nematodes—encompassing both standard and genetically engineered strains. Our models mimic key features of human obesity, such as excessive adiposity, metabolic dysfunction, and associated comorbidities, thereby providing a scientifically rigorous platform for pharmacological testing, mechanistic studies, and biomarker discovery. This diversity ensures that our clients can select the most appropriate model to address their specific research questions and therapeutic targets.

Diet-Induced Obesity (DIO) Models

Diet-Induced Obesity (DIO) models are established by feeding animals a high-fat, high-sugar, or high-calorie diet over a defined period, leading to weight gain, increased adiposity, and metabolic disturbances similar to those observed in human obesity. Commonly used species include C57BL/6J mice, Sprague Dawley rats, and other rodent and non-rodent models such as hamsters, rabbits, dogs, and nonhuman primates. DIO models are highly relevant for evaluating the efficacy of anti-obesity drugs, nutritional interventions, and lifestyle modifications. Key advantages include their close mimicry of human lifestyle-induced obesity and metabolic syndrome, as well as their suitability for longitudinal studies and combination therapy testing. Primary applications include drug screening, metabolic profiling, and assessment of comorbidities such as insulin resistance, dyslipidemia, and hepatic steatosis.

Genetic and Transgenic Obesity Models

Genetic and transgenic models involve animals with targeted gene mutations, knockouts, or transgenic modifications that predispose them to obesity. Examples include ob/ob (leptin-deficient) and db/db (leptin receptor-deficient) mice, Zucker rats, and a wide array of conditional knockout and transgenic lines affecting key regulators of energy balance, appetite, and metabolism (e.g., Mc4r, Ucp1, Adipoq, Glp1r, etc.). These models provide valuable insights into the molecular mechanisms underlying obesity and allow for the study of gene-environment and gene-drug interactions. Their main advantages are reproducibility, defined genetic backgrounds, and the ability to dissect specific pathways involved in obesity. Applications encompass target validation, mechanistic studies, and evaluation of gene-based or personalized therapies.

Chemically-Induced Obesity Models

Chemically-induced models utilize pharmacological agents (such as glucose, olanzapine, fructose, corticosterone, or lipopolysaccharide) to induce obesity or related metabolic disturbances in various animal species. Administration routes and dosing regimens are optimized to generate phenotypes such as hyperphagia, insulin resistance, and increased adiposity. These models are particularly useful for studying drug-induced obesity, metabolic side effects of medications, and for rapid induction of specific metabolic derangements. Key advantages include rapid onset, controllable induction, and relevance for evaluating the metabolic impact of candidate compounds. They are widely used for pharmacodynamic studies, safety pharmacology, and mechanistic investigations of drug action.

Surgical and Special Condition Models

Surgical and special condition models include interventions such as ovariectomy, hypothalamic lesions, vagotomy, or bariatric procedures (e.g., Roux-en-Y gastric bypass) to induce obesity or alter metabolic status. These models are instrumental for exploring the roles of endocrine, neural, and gastrointestinal factors in obesity pathogenesis and treatment. Advantages include the ability to mimic specific clinical scenarios (such as post-menopausal obesity or post-bariatric surgery outcomes) and to dissect organ-specific contributions to energy homeostasis. Applications include evaluation of hormone replacement therapies, neural regulation of appetite, and post-surgical metabolic adaptations.

Protheragen delivers end-to-end in vivo obesity model development services, from model selection and study design to execution, data analysis, and reporting. Our offerings include customized diet formulations, genetic engineering, chemical induction protocols, and surgical techniques to match your research objectives. Key efficacy endpoints and measurements encompass body weight, body composition (DXA, MRI), food intake, glucose and insulin tolerance tests, lipid profiles, energy expenditure (indirect calorimetry), histopathology (adipose tissue, liver), and molecular biomarker analysis. Our analytical capabilities extend to advanced omics (transcriptomics, metabolomics), imaging, and immunophenotyping. Rigorous quality control is maintained through standardized protocols, validated assays, ethical compliance, and comprehensive data integrity checks, ensuring reproducibility and regulatory readiness.

Partnering with Protheragen provides you with access to a diverse portfolio of validated obesity models, expert scientific guidance, and a commitment to high-quality, translational research. Our flexible, client-focused approach ensures that your preclinical studies are robust, efficient, and tailored to accelerate the development of effective anti-obesity therapies. Contact us today to discuss your project needs and discover how our in vivo obesity model services can advance your research goals.